Viewing Study NCT00183898



Ignite Creation Date: 2024-05-05 @ 11:57 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00183898
Status: UNKNOWN
Last Update Posted: 2019-05-16
First Post: 2005-09-09

Brief Title: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Sponsor: University of Southern California
Organization: University of Southern California

Study Overview

Official Title: Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Status: UNKNOWN
Status Verified Date: 2019-05
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is for people with advanced gastric or gastroesophageal cancer This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine oxaliplatin and cetuximab Capecitabine also called Xeloda is a drug that has been approved by the Food and Drug Administration FDA Capecitabine has been approved for treatment of cancer of the colon and rectum Oxaliplatin is another drug approved by the FDA Oxaliplatin is also approved for treatment of cancer of the colon and rectum Cetuximab is also a drug approved by the FDA for the treatment of cancer of the colon and rectum as well as cancer of the head and neck Capecitabine oxaliplatin and cetuximab are not approved for gastric or gastroesophageal cancer They are considered experimental drugs for this study The purpose of this study is to see how long it takes patients tumors to progress when they are taking oxaliplatin and capecitabine Another purpose is to see how many tumors respond to this drug combination The investigators also want to see how long people live when taking these drugs The side effects of this drug combination will also be evaluated This study will also measure the levels of certain genes the cells blueprint in tumors These genes affect how peoples bodies react to the cancer drugs Genes will also be measured in the blood The investigators want to see how these genes can predict response to these study drugs
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None